» Articles » PMID: 26869584

Association of Macroeconomic Factors With Nonrelapse Mortality After Allogeneic Hematopoietic Cell Transplantation for Adults With Acute Lymphoblastic Leukemia: An Analysis From the Acute Leukemia Working Party of the EBMT

Abstract

Purpose: From a global perspective, the rates of allogeneic hematopoietic cell transplantation (alloHCT) are closely related to the economic status of a country. However, a potential association with outcome has not yet been documented. The goal of this study was to evaluate effects of health care expenditure (HCE), Human Development Index (HDI), team density, and center experience on nonrelapse mortality (NRM) after HLA-matched sibling alloHCT for adults with acute lymphoblastic leukemia (ALL).

Patients And Methods: A total of 983 patients treated with myeloablative alloHCT between 2004 and 2008 in 24 European countries were included.

Results: In a univariate analysis, the probability of day 100 NRM was increased for countries with lower current HCE (8% vs. 3%; p = .06), countries with lower HDI (8% vs. 3%; p = .02), and centers with less experience (8% vs. 5%; p = .04). In addition, the overall NRM was increased for countries with lower current HCE (21% vs. 17%; p = .09) and HDI (21% vs. 16%; p = .03) and for centers with lower activity (21% vs. 16%; p = .07). In a multivariate analysis, the strongest predictive model for day 100 NRM included current HCE greater than the median (hazard ratio [HR], 0.39; p = .002). The overall NRM was mostly predicted by HDI greater than the median (HR, 0.65; p = .01). Both lower current HCE and HDI were associated with decreased probability of overall survival.

Conclusion: Both macroeconomic factors and the socioeconomic status of a country strongly influence NRM after alloHCT for adults with ALL. Our findings should be considered when clinical studies in the field of alloHCT are interpreted.

Citing Articles

Temporal trends in Hematopoietic Stem Cell Transplantation in Argentina: regional differences that mirror the global reality.

Rego E Hematol Transfus Cell Ther. 2023; 45(2):145-146.

PMID: 37268346 PMC: 10244239. DOI: 10.1016/j.htct.2023.05.001.


Impact of Center-related Characteristics and Macroeconomic Factors on the Outcome of Adult Patients With Acute Lymphoblastic Leukemia Treated With Pediatric-inspired Protocols.

Barba P, Morgades M, Montesinos P, Gonzalez-Campos J, Torrent A, Gil C Hemasphere. 2022; 7(1):e810.

PMID: 36583094 PMC: 9794204. DOI: 10.1097/HS9.0000000000000810.


Increasing access to allogeneic hematopoietic cell transplant: an international perspective.

Rocha V, Fatobene G, Niederwieser D Hematology Am Soc Hematol Educ Program. 2021; 2021(1):264-274.

PMID: 34889391 PMC: 8791161. DOI: 10.1182/hematology.2021000258.


Association of Country-Specific Socioeconomic Factors With Survival of Patients Who Experience Severe Classic Acute Graft-vs.-Host Disease After Allogeneic Hematopoietic Cell Transplantation. An Analysis From the Transplant Complications Working....

Frankiewicz A, Peczynski C, Giebel S, Harrington A, Socie G, Niederwieser D Front Immunol. 2020; 11:1537.

PMID: 32793210 PMC: 7390847. DOI: 10.3389/fimmu.2020.01537.


Country-Level Macroeconomic Indicators Predict Early Post-Allogeneic Hematopoietic Cell Transplantation Survival in Acute Lymphoblastic Leukemia: A CIBMTR Analysis.

Wood W, Brazauskas R, Hu Z, Abdel-Azim H, Ahmed I, Aljurf M Biol Blood Marrow Transplant. 2018; 24(9):1928-1935.

PMID: 29567340 PMC: 6146070. DOI: 10.1016/j.bbmt.2018.03.016.


References
1.
Gratwohl A, Baldomero H, Aljurf M, Pasquini M, Bouzas L, Yoshimi A . Hematopoietic stem cell transplantation: a global perspective. JAMA. 2010; 303(16):1617-24. PMC: 3219875. DOI: 10.1001/jama.2010.491. View

2.
Frassoni F, Labopin M, Powles R, Mary J, Arcese W, Bacigalupo A . Effect of centre on outcome of bone-marrow transplantation for acute myeloid leukaemia. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet. 2000; 355(9213):1393-8. DOI: 10.1016/s0140-6736(00)02137-1. View

3.
Horowitz M, Przepiorka D, Champlin R, Gale R, Gratwohl A, Herzig R . Should HLA-identical sibling bone marrow transplants for leukemia be restricted to large centers?. Blood. 1992; 79(10):2771-4. View

4.
Sharma S, Choudhary D, Gupta N, Dhamija M, Khandelwal V, Kharya G . Cost of hematopoietic stem cell transplantation in India. Mediterr J Hematol Infect Dis. 2014; 6(1):e2014046. PMC: 4103507. DOI: 10.4084/MJHID.2014.046. View

5.
Gratwohl A . The EBMT risk score. Bone Marrow Transplant. 2011; 47(6):749-56. DOI: 10.1038/bmt.2011.110. View